|
Search
Collections
Benchmarks
Upload document
Product
cenegermin-bkbj
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Neurotrophic Keratopathy
Clinical trial
An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE™ 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)
Status: Completed
, Estimated PCD: 2021-09-30
